Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $10.7 million.

  • SAB Biotherapeutics' Shares Outstanding (Weighted Average) rose 1513.42% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 million, marking a year-over-year increase of 1513.42%. This contributed to the annual value of $9.3 million for FY2024, which is 6774.32% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Shares Outstanding (Weighted Average) stood at $10.7 million, which was up 1513.42% from $9.3 million recorded in Q2 2025.
  • SAB Biotherapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $43.0 million during Q2 2022, with a 5-year trough of $4.4 million in Q4 2022.
  • Over the past 5 years, SAB Biotherapeutics' median Shares Outstanding (Weighted Average) value was $9.3 million (recorded in 2024), while the average stood at $15.0 million.
  • In the last 5 years, SAB Biotherapeutics' Shares Outstanding (Weighted Average) surged by 99356.72% in 2021 and then plummeted by 8828.73% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $27.3 million in 2021, then crashed by 84.08% to $4.4 million in 2022, then grew by 26.86% to $5.5 million in 2023, then skyrocketed by 67.74% to $9.3 million in 2024, then rose by 15.1% to $10.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $10.7 million for Q3 2025, versus $9.3 million for Q2 2025 and $9.3 million for Q1 2025.